Anti-obesity Medication Semaglutide (Wegovy®) Could Benefit Millions of Americans With Obesity and Cardiovascular Disease
The medication has the potential to markedly reduce the risk of heart attacks and other heart-related conditions among millions of Americans with obesity who have also been diagnosed with cardiovascular disease, a Yale study shows.
First White House Initiative on Women’s Health Research to Be Directed by Yale’s Carolyn M. Mazure
President Biden has announced the launch of the new White House Initiative on Women’s Health Research, to be led by first lady Jill Biden and directed by Carolyn M. Mazure, PhD, founder and director of Yale School of Medicine’s Women’s Health Research at Yale.
Novo Nordisk’s Weight Loss Drug Wegovy Slashes Risk of Serious Heart Events
Ania Jastreboff, MD, PhD, associate professor of medicine (endocrinology), weighs in on a study that showed Wegovy reduced the risk of of serious cardiovascular events in people with obesity and heart disease.Source: CNBC
Cavallo Named to American Urological Association Task Force
Jaime Cavallo, MD, MPHS, assistant professor of urology, was recently named inaugural director of the New England section of the American Urological Association's (NEAUA) DEI task force, also making her a member of the NEAUA's board of directors.
Yale Cancer Center Researchers Awarded 2023-2024 Grants from the Breast Cancer Research Foundation
The Breast Cancer Research Foundation (BCRF) Scientific Advisory Board and its Board of Directors recently announced its $60.2 million commitment to fund breast cancer research in 2023-2024, supporting more than 250 scientists at leading academic and medical institutions, including eight grants at Yale Cancer Center and Smilow Cancer Hospital.
Radioligand Therapy Improves PFS and Responses in SSTR+ Grade 2/3 GEP-NETs
The use of lutetium 177Lu dotatate (Lutathera) and high-dose long-acting octreotide as frontline treatment for patients with newly diagnosed somatostatin receptor (SSTR)-positive, grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) led to significant improvements in progression-free survival (PFS) compared with high-dose long-acting octreotide alone. "This would represent a new indication for first-line treatment of GEP-NETS. In addition, this would represent the first theranostic agent FDA approved for use in the 1st line setting," said Kunz, associate professor of Internal Medicine (Medical Oncology); director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; chief, GI Medical Oncology; vice chief, Diversity, Equity, and Inclusion, Medical Oncology.Source: Targeted Oncology
Investigators Launch Study Aimed at Accelerating Understanding of Bipolar Disorder
A multidisciplinary team of researchers based at Yale will launch a series of studies aimed at accelerating understanding of bipolar disorder and generating new and more effective treatments. Hilary Blumberg, MD, John and Hope Furth Professor of Psychiatric Neuroscience and Professor of Psychiatry, and in the Child Study Center and of Radiology and Biomedical Imaging, will lead the research team.
Mitochondrial Function: Beyond Serving as the ‘Powerhouse of the Cell’
A new study shows that mitochondria help determine what undifferentiated cells in a growing embryo eventually will become. The study reveals a new underlying biological mechanism of mitochondrial metabolism and has important implications for treating diseases such as cancer.